ZYME stock forecast, quote, news & analysis
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics... Show more
Why Zymeworks (ZYME) Stock Is Down -13% in the Last 30 Days
Key Takeaways
- Zymeworks (ZYME) shares declined approximately 13% over the past 30 days, falling from $26.14 on June 30, 2026, to $22.71 as of July 30, 2026.
- Over the broader quarterly period, the stock shed roughly 18% from its April 30 close of $27.54, reflecting sustained selling pressure.
- The pending $929 million acquisition of Theravance Biopharma remains the dominant narrative, with investor focus shifting to integration risks and deal-closing timelines.
- Wall Street analysts remain broadly constructive, with price targets ranging from $31 to $46 and a consensus "Moderate Buy" rating, though near-term sentiment has cooled.
- A $125 million share buyback program and encouraging Phase 1 data for the ZW191 ADC candidate provide fundamental support but have not offset recent downward momentum.
Zymeworks (ZYME) Company Overview and Market Position
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a pipeline of novel multifunctional biotherapeutics targeting cancer, inflammation, and autoimmune diseases. The company's flagship asset is Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using its proprietary Azymetric platform and licensed to Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene) in different global territories. Zymeworks has transitioned toward a hybrid royalty-aggregation model, combining internal R&D with strategic acquisitions of revenue-generating royalty streams. The company's antibody-drug conjugate (ADC) pipeline includes ZW191 and ZW251, both in Phase 1 trials, and it maintains research partnerships with major biopharmaceutical firms including Johnson & Johnson, GSK, and Daiichi Sankyo.
Zymeworks (ZYME) Stock Price Performance: Last 30 Days vs. Quarter
ZYME shares closed at $26.14 on June 30, 2026, and traded at $22.71 on July 30, 2026, representing a decline of approximately 13% during the 30-day window. The stock touched a peak of $27.07 on July 9 before entering a sustained downtrend that accelerated in the second half of the month, with the stock falling below the $23 mark in late July. Over the broader quarterly period from late April, when shares closed at $27.54, the decline extends to roughly 18%. The 50-day moving average has slipped to approximately $24.67, and the stock now trades below both its 50-day and 200-day moving averages, signaling a technical breakdown from the range observed through much of the spring and early summer.
What Drove ZYME Stock Price in the Last 30 Days
The 30-day pullback was shaped by several converging factors. The acquisition of Theravance Biopharma, announced earlier in 2026 and valued at approximately $929 million in cash, remained the dominant corporate event. While analysts at Wells Fargo and Truist raised price targets to $37 and $31 respectively following the deal, the market appeared to digest the execution risks associated with integrating Theravance's commercial-stage respiratory assets, including YUPELRI and contingent payments tied to GSK's Trelegy inhaler. Investor concern about the deal's financing structure—which includes $350 million in non-recourse senior secured notes from OMERS Life Sciences—contributed to the cautious tone. Additionally, Zymeworks was dropped from several Russell indices following the annual reconstitution, triggering forced selling from passive funds that track those benchmarks. The company's announcement on July 16 that it would not host a Q2 earnings conference call, citing the pending Theravance acquisition, removed a key near-term catalyst and left the market without forward guidance during a sensitive period. Broader biotech sector headwinds and profit-taking after the stock's strong rally earlier in 2026 compounded the selling pressure.
What Drove ZYME Stock Performance Over the Last Quarter
The quarterly decline of approximately 18% reflects a broader reassessment of Zymeworks' risk-reward profile following a period of significant corporate transformation. The stock entered the quarter near $27.54 and experienced a sharp single-day drop of roughly 10% on May 8, when shares fell from $26.60 to $23.89 amid what appeared to be a broad repositioning event, possibly linked to the Russell index removal and post-acquisition portfolio rebalancing by institutional holders. The stock subsequently recovered into the $25–$27 range through June and early July before the recent leg lower. Throughout the quarter, Zymeworks reported encouraging clinical data, including confirmed objective response rates of 78.6% for ZW191 in FRα-positive ovarian tumors, and authorized a $125 million share repurchase program—executing $102.3 million in buybacks through mid-May. However, the transition to a royalty-aggregation model, while strategically compelling, has introduced new complexity: investors are now evaluating the company on both biotech pipeline execution and deal-integration capabilities, with the Theravance closing expected in the second half of 2026 leaving a multi-month information gap.
Trending AI Robots
For traders seeking data-driven strategies in volatile markets like biotechnology, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI-powered trading bots. Tickeron hosts hundreds of algorithmic trading bots that trade across thousands of tickers, but only those demonstrating consistently strong performance and relevance are featured in this section. Each bot operates with distinct strategies, timeframes, and performance metrics—ranging from short-term swing trading to longer-duration trend-following models—allowing traders to identify approaches aligned with their own risk tolerance and objectives. Explore the Trending AI Robots page to see which strategies are currently generating signals in this dynamic market environment.
ZYME Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for ZYME is its second-quarter 2026 financial results, scheduled for release after market close on August 6. Although no conference call will be held, the earnings release will provide critical updates on cash position, operating expenses, and the timeline for closing the Theravance Biopharma acquisition. Investors should monitor any disclosures about the deal-financing package, regulatory approvals, and expected synergies from the combined entity. On the clinical front, additional data readouts from the Phase 1 trials of ZW191 and ZW251, as well as potential partnership announcements for early-stage ADC programs, could influence sentiment. Macroeconomic factors—including interest-rate expectations and biotech sector fund flows—remain relevant for a pre-revenue company trading on pipeline and royalty potential. The pace and scale of the ongoing $125 million buyback may also serve as a signal of management's conviction in the stock's intrinsic value during this period of transition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZYME's RSI Oscillator recovers from oversold territory
The RSI Indicator for ZYME moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
ZYME moved below its 50-day moving average on July 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ZYME crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZYME broke above its upper Bollinger Band on June 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on June 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.872) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (420.906).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company for cancer & autoimmune treatment
Industry Biotechnology